10 results · 21ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

CORE DISPOSABLE SUCTION/IRRIGATION TUBING

FDA 510(k)
FDA Class 2 ·Gastroenterology, Urology

DeRoyal

FDA UDI
DEROYAL INDUSTRIES, INC.·00749756363044·VAGINAL SURGERY PACK

MEDISIZE RED AND MEDISIZE BLUE

FDA 510(k)
FDA Class 2 ·Anesthesiology

KYPHX INFLATABLE BONE TAMP, SIZE 20/3,MODEL K01A, KYPHX INFLATABLE BONE TAMP, SIZE 15/3, MODEL K02A

FDA 510(k)
FDA Class 2 ·Orthopedic

FLEXTEND II

FDA Adverse Event
Injury ·CPI - DEL CARIBE·Product code NVN·January 11, 2013

SETROX S 53

FDA Adverse Event
Injury ·BIOTRONIK SE & CO. KG·Product code NVZ·November 22, 2010

ULTRAFLEX

FDA Adverse Event
Injury ·BOSTON SCIENTIFIC - GALWAY·Product code ESW·July 2, 2014

NOVATION Femoral Stem, Tapered Extended offset, plasma- coated, press fit. Catalog number 160-01-13 intended to be implanted to replace a hip joint with our without bone cement.

FDA Enforcement
Class II ·Terminated·Exactech, Inc.·July 30, 2014

TCM4 series Base Units, and spare part Power Supply, Radiometer Medical ApS, Akandevej 21, Br¿nsh¿j, Denmark, www.radiometer.com. The devices are intended for continuous monitoring of carbon dioxide and oxygen partial pressures, oxygen saturation, and pulse rate.

FDA Enforcement
Class II ·Terminated·Radiometer America Inc·August 14, 2013

Assurity Model Numbers: PM1240, PM2240; Assurity + Model Number: PM2260; Accent Model Numbers: PM1210, PM2210, PM1222, PM2212; Accent MRI Model Numbers: PM1224, PM2218, PM2224 Implantation of a single-chamber pulse generator, dual-chamber pulse generator, or CRT-P is indicated in one or more of the following permanent conditions: Syncope, Presyncope, Fatigue, Disorientation, Or any combination of those symptoms. Implantation of a CRT-P is indicated for: Maintaining synchrony of the left and right ventricles in patients who have undergone an AV nodal ablation for chronic atrial fibrillation and have NYHA Class II or III heart failure. The reduction of the symptoms of moderate to severe heart failure (NYHA Class III or IV) in those patients who remain symptomatic despite stable, optimal medical therapy, and have a left ventricular ejection fraction d35% and a prolonged QRS duration

FDA Enforcement
Class II ·Terminated·St Jude Medical Inc.·October 25, 2017